Literature DB >> 33616613

Effect of Telephone Cognitive Behavioral Therapy for Insomnia in Older Adults With Osteoarthritis Pain: A Randomized Clinical Trial.

Susan M McCurry1, Weiwei Zhu2, Michael Von Korff2, Robert Wellman2, Charles M Morin3, Manu Thakral2,4, Kai Yeung2, Michael V Vitiello5.   

Abstract

Importance: Scalable delivery models of cognitive behavioral therapy for insomnia (CBT-I), an effective treatment, are needed for widespread implementation, particularly in rural and underserved populations lacking ready access to insomnia treatment. Objective: To evaluate the effectiveness of telephone CBT-I vs education-only control (EOC) in older adults with moderate to severe osteoarthritis pain. Design, Setting, and Participants: This is a randomized clinical trial of 327 participants 60 years and older who were recruited statewide through Kaiser Permanente Washington from September 2016 to December 2018. Participants were double screened 3 weeks apart for moderate to severe insomnia and osteoarthritis (OA) pain symptoms. Blinded assessments were conducted at baseline, after 2 months posttreatment, and at 12-month follow-up. Interventions: Six 20- to 30-minute telephone sessions provided over 8 weeks. Participants submitted daily diaries and received group-specific educational materials. The CBT-I instruction included sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and homework. The EOC group received information about sleep and OA. Main Outcomes and Measures: The primary outcome was score on the Insomnia Severity Index (ISI) at 2 months posttreatment and 12-month follow-up. Secondary outcomes included pain (score on the Brief Pain Inventory-short form), depression (score on the 8-item Patient Health Questionnaire), and fatigue (score on the Flinders Fatigue Scale).
Results: Of the 327 participants, the mean (SD) age was 70.2 (6.8) years, and 244 (74.6%) were women. In the 282 participants with follow-up ISI data, the total 2-month posttreatment ISI scores decreased 8.1 points in the CBT-I group and 4.8 points in the EOC group, an adjusted mean between-group difference of -3.5 points (95% CI, -4.4 to -2.6 points; P < .001). Results were sustained at 12-month follow-up (adjusted mean difference, -3.0 points; 95% CI, -4.1 to -2.0 points; P < .001). At 12-month follow-up, 67 of 119 (56.3%) participants receiving CBT-I remained in remission (ISI score, ≤7) compared with 33 of 128 (25.8%) participants receiving EOC. Fatigue was also significantly reduced in the CBT-I group compared with the EOC group at 2 months posttreatment (mean between-group difference, -2.0 points; 95% CI, -3.1 to -0.9 points; P = <.001) and 12-month follow-up (mean between-group difference, -1.8 points; 95% CI, -3.1 to -0.6 points; P = .003). Posttreatment significant differences were observed for pain, but these differences were not sustained at 12-month follow-up. Conclusions and Relevance: In this randomized clinical trial, telephone CBT-I was effective in improving sleep, fatigue, and, to a lesser degree, pain among older adults with comorbid insomnia and OA pain in a large statewide health plan. Results support provision of telephone CBT-I as an accessible, individualized, effective, and scalable insomnia treatment. Trial Registration: Clinical Trials.gov Identifier: NCT02946957.

Entities:  

Mesh:

Year:  2021        PMID: 33616613      PMCID: PMC7900930          DOI: 10.1001/jamainternmed.2020.9049

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN: 2168-6106            Impact factor:   21.873


  9 in total

1.  Cost-effectiveness of telephone cognitive behavioral therapy for osteoarthritis-related insomnia.

Authors:  Kai Yeung; Weiwei Zhu; Susan M McCurry; Michael Von Korff; Robert Wellman; Charles M Morin; Michael V Vitiello
Journal:  J Am Geriatr Soc       Date:  2021-10-11       Impact factor: 5.562

2.  Long-term improvements in sleep, pain, depression, and fatigue in older adults with comorbid osteoarthritis pain and insomnia.

Authors:  Michael V Vitiello; Weiwei Zhu; Michael Von Korff; Robert Wellman; Charles M Morin; Kai Yeung; Susan M McCurry
Journal:  Sleep       Date:  2022-02-14       Impact factor: 6.313

Review 3.  Applications of Digital Health Technologies in Knee Osteoarthritis: Narrative Review.

Authors:  Nirali Shah; Kerry Costello; Akshat Mehta; Deepak Kumar
Journal:  JMIR Rehabil Assist Technol       Date:  2022-06-08

4.  Prevention of Incident and Recurrent Major Depression in Older Adults With Insomnia: A Randomized Clinical Trial.

Authors:  Michael R Irwin; Carmen Carrillo; Nina Sadeghi; Martin F Bjurstrom; Elizabeth C Breen; Richard Olmstead
Journal:  JAMA Psychiatry       Date:  2022-01-01       Impact factor: 21.596

5.  Classifying chronic pain using multidimensional pain-agnostic symptom assessments and clustering analysis.

Authors:  Gadi Gilam; Eric M Cramer; Kenneth A Webber; Maisa S Ziadni; Ming-Chih Kao; Sean C Mackey
Journal:  Sci Adv       Date:  2021-09-08       Impact factor: 14.136

6.  Acupuncture versus cognitive behavioral therapy for pain among cancer survivors with insomnia: an exploratory analysis of a randomized clinical trial.

Authors:  Mingxiao Yang; Kevin T Liou; Sheila N Garland; Ting Bao; Tony K W Hung; Susan Q Li; Yuelin Li; Jun J Mao
Journal:  NPJ Breast Cancer       Date:  2021-11-30

Review 7.  Neuroimaging Mechanism of Cognitive Behavioral Therapy in Pain Management.

Authors:  Shangyi Bao; Mengyuan Qiao; Yutong Lu; Yunlan Jiang
Journal:  Pain Res Manag       Date:  2022-02-02       Impact factor: 3.037

Review 8.  Effectivity of (Personalized) Cognitive Behavioral Therapy for Insomnia in Mental Health Populations and the Elderly: An Overview.

Authors:  Teus Mijnster; Gretha J Boersma; Esther Meijer; Marike Lancel
Journal:  J Pers Med       Date:  2022-06-29

Review 9.  Sleep Health Assessment and Treatment in Children and Adolescents with Chronic Pain: State of the Art and Future Directions.

Authors:  Emily F Law; Agnes Kim; Kelly Ickmans; Tonya M Palermo
Journal:  J Clin Med       Date:  2022-03-09       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.